Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
Key takeaways
- (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli?
- Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock.
- A significant corporate development occurred on June 17, when Ocular Therapeuticx, Inc.
Is Ocular Therapeuticx, Inc. (OCUL) Stock Positioned for Growth After Positive FDA Feedback on Axpaxli? Laiba Immad Thu, June 25, 2026 at 7:40 PM GMT+7 2 min read OCUL We recently compiled a list of the 10 Best Healthcare Stocks to Buy According to Wall Street Analysts. Ocular Therapeuticx, Inc. (NASDAQ:OCUL) is among the best healthcare stocks.
The Fly reported on June 18 that H.C. Wainwright increased its price target on OCUL to $25 from $21 while maintaining a Buy rating on the stock. The firm's updated outlook followed the company's discussion of feedback received during a recent Type C meeting with the FDA at its investor day event. H.C. Wainwright indicated that the regulatory update strengthened confidence in Axpaxli's commercial potential, leading to higher projections for peak annual revenue and an improved assessment of the therapy's likelihood of obtaining regulatory approval. The firm also noted expectations for strong physician uptake and broad market penetration following a potential launch.
A significant corporate development occurred on June 17, when Ocular Therapeuticx, Inc. (NASDAQ:OCUL) outlined its regulatory strategy for AXPAXLI in wet age-related macular degeneration. The company announced plans to submit a New Drug Application in the fourth quarter of 2026 using efficacy and safety results from the SOL-1 trial alongside interim safety findings from SOL-R. OCUL also revised the SOL-R study design to continue evaluating additional endpoints through Week 96 and further differentiate AXPAXLI from existing treatments. In addition, the company streamlined its non-proliferative diabetic retinopathy development program by concentrating resources on the Phase 3 HELIOS-3 trial.